These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16610801)

  • 1. Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
    Dolman NP; More JC; Alt A; Knauss JL; Troop HM; Bleakman D; Collingridge GL; Jane DE
    J Med Chem; 2006 Apr; 49(8):2579-92. PubMed ID: 16610801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
    Dolman NP; Troop HM; More JC; Alt A; Knauss JL; Nistico R; Jack S; Morley RM; Bortolotto ZA; Roberts PJ; Bleakman D; Collingridge GL; Jane DE
    J Med Chem; 2005 Dec; 48(24):7867-81. PubMed ID: 16302825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.
    Dolman NP; More JC; Alt A; Knauss JL; Pentikäinen OT; Glasser CR; Bleakman D; Mayer ML; Collingridge GL; Jane DE
    J Med Chem; 2007 Apr; 50(7):1558-70. PubMed ID: 17348638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists.
    More JC; Troop HM; Dolman NP; Jane DE
    Br J Pharmacol; 2003 Mar; 138(6):1093-100. PubMed ID: 12684265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine.
    Patneau DK; Mayer ML; Jane DE; Watkins JC
    J Neurosci; 1992 Feb; 12(2):595-606. PubMed ID: 1371315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes.
    Jane DE; Hoo K; Kamboj R; Deverill M; Bleakman D; Mandelzys A
    J Med Chem; 1997 Oct; 40(22):3645-50. PubMed ID: 9357531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Willardiines differentiate agonist binding sites for kainate- versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons.
    Wong LA; Mayer ML; Jane DE; Watkins JC
    J Neurosci; 1994 Jun; 14(6):3881-97. PubMed ID: 7515954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel antagonist 3-CBW discriminates between kainate receptors expressed on neonatal rat motoneurones and those on dorsal root C-fibres.
    More JC; Troop HM; Jane DE
    Br J Pharmacol; 2002 Dec; 137(7):1125-33. PubMed ID: 12429586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist.
    More JC; Nistico R; Dolman NP; Clarke VR; Alt AJ; Ogden AM; Buelens FP; Troop HM; Kelland EE; Pilato F; Bleakman D; Bortolotto ZA; Collingridge GL; Jane DE
    Neuropharmacology; 2004 Jul; 47(1):46-64. PubMed ID: 15165833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-hydroxypyridazine 1-oxides as carboxylate bioisosteres: a new series of subtype-selective AMPA receptor agonists.
    Greenwood JR; Mewett KN; Allan RD; Martín BO; Pickering DS
    Neuropharmacology; 2006 Jul; 51(1):52-9. PubMed ID: 16631211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of kainate receptors reduces the frequency of hippocampal theta oscillations.
    Huxter JR; Zinyuk LE; Roloff Ev; Clarke VR; Dolman NP; More JC; Jane DE; Collingridge GL; Muller RU
    J Neurosci; 2007 Feb; 27(9):2212-23. PubMed ID: 17329418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.
    Alt A; Weiss B; Ogden AM; Li X; Gleason SD; Calligaro DO; Bleakman D; Witkin JM
    Psychopharmacology (Berl); 2006 Apr; 185(2):240-7. PubMed ID: 16470401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
    Weiss B; Alt A; Ogden AM; Gates M; Dieckman DK; Clemens-Smith A; Ho KH; Jarvie K; Rizkalla G; Wright RA; Calligaro DO; Schoepp D; Mattiuz EL; Stratford RE; Johnson B; Salhoff C; Katofiasc M; Phebus LA; Schenck K; Cohen M; Filla SA; Ornstein PL; Johnson KW; Bleakman D
    J Pharmacol Exp Ther; 2006 Aug; 318(2):772-81. PubMed ID: 16690725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of the new radioligand (S)-[3H]AMPA to rat brain synaptic membranes: effects of a series of structural analogues of the non-NMDA receptor agonist willardiine.
    Hawkins LM; Beaver KM; Jane DE; Taylor PM; Sunter DC; Roberts PJ
    Neuropharmacology; 1995 Apr; 34(4):405-10. PubMed ID: 7566471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiallodynic and antihyperalgesic effects of selective competitive GLUK5 (GluR5) ionotropic glutamate receptor antagonists in the capsaicin and carrageenan models in rats.
    Jones CK; Alt A; Ogden AM; Bleakman D; Simmons RM; Iyengar S; Dominguez E; Ornstein PL; Shannon HE
    J Pharmacol Exp Ther; 2006 Oct; 319(1):396-404. PubMed ID: 16837561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological differentiation of kainate receptors on neonatal rat spinal motoneurones and dorsal roots.
    Thomas NK; Hawkins LM; Miller JC; Troop HM; Roberts PJ; Jane DE
    Neuropharmacology; 1998; 37(10-11):1223-37. PubMed ID: 9849660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium inhibits willardiine-induced responses in kainate receptor GluR6(Q)/KA-2.
    Fukushima T; Marshall J; Sakata K; Shingai R
    Neuroreport; 2001 Jan; 12(1):163-7. PubMed ID: 11201079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro characterization of 5-carboxyl-2,4-di-benzamidobenzoic acid (NS3763), a noncompetitive antagonist of GLUK5 receptors.
    Christensen JK; Varming T; Ahring PK; Jørgensen TD; Nielsen EØ
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1003-10. PubMed ID: 14985418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonist pharmacology of kainate- and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors.
    Wilding TJ; Huettner JE
    Mol Pharmacol; 1996 Mar; 49(3):540-6. PubMed ID: 8643094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacological investigation of the role of GLUK5-containing receptors in kainate-driven hippocampal gamma band oscillations.
    Brown JT; Teriakidis A; Randall AD
    Neuropharmacology; 2006 Jan; 50(1):47-56. PubMed ID: 16153668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.